Remdesivir for the Treatment of Covid-19—Preliminary Report

TAKE-HOME MESSAGE

Adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement were randomized to receive intravenous remdesivir or placebo for up to 10 days. Median recovery time was 11 days in the remdesivir group versus 15 days in the placebo group (P < .001). The estimated mortality rate at 14 days was 7.1% with remdesivir and 11.9% with placebo. The risk of serious adverse events was 21.1% in the remdesivir group and 27.0% in the placebo group.

Remdesivir was associated with a shortened time to recovery compared with placebo in adults hospitalized with Covid-19 and with lower respiratory tract involvement.